Skip to content

Comparison of Huoxiang Anwei Granules and Huoxiang Anwei Powder in the Treatment of Helicobacter pylori Infection: A Randomized Controlled Clinical Study

Comparison of Huoxiang Anwei Granules and Huoxiang Anwei Powder in the Treatment of Helicobacter pylori Infection: A Randomized Controlled Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116053
Enrollment
Unknown
Registered
2026-01-05
Start date
2024-06-17
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori

Interventions

Western Medicine Group:Standard quadruple therapy, course of treatment 2 weeks.
Huoxiang Anwei Powder Group:Administer Huoxiang Anwei San, 1 dose/day, in combination with standard quadruple therapy, for a course of 2 weeks.
Huoxiang Anwei Granules Group:Administer Huoxiang Anwei Granules, 1 bag/time, 2 times/day, in combination with standard quadruple therapy, for a course of 2 weeks.

Sponsors

Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for H. pylori infection; (2) Age between 18 and 65 years old; (3) Voluntarily accept the experiment and sign the informed consent form; (4) Normal cognitive function, no reading or writing disabilities; Be able to actively cooperate and participate in research and investigation.

Exclusion criteria

Exclusion criteria: (1) Patients with severe lesions in major organs such as liver, liver, and kidneys, hematopoietic system diseases, and tumors; (2) Used antibiotics, acid suppressants, and bismuth supplements within 4 weeks prior to treatment; (3) Systemic diseases that affect digestive tract dynamics (such as hyperthyroidism, diabetes, chronic renal insufficiency, mental and nervous system diseases, etc.); (4) History of upper gastrointestinal bleeding, partial gastrectomy, severe gastric mucosal atrophy/intestinal metaplasia, etc; (5) Pregnant or breastfeeding women who are preparing for pregnancy; (6) Individuals with a history of allergies to the drugs used in this study; (7) Patients with severe primary and mental illnesses; (8) Subjects currently participating in other clinical trials; (9) The screening period test results indicate that ALT and AST values exceed the upper limit of the normal range by 2 times, and total bilirubin and BUN values exceed the upper limit of the normal range by 1.5 times.

Design outcomes

Primary

MeasureTime frame
13 C-urea breath test;Chinese Medicine Syndrome Scale Score;

Secondary

MeasureTime frame
Adverse reaction occurrence;Improvement in quality of life;Degree of relief of anxiety and depression;

Countries

China

Contacts

Public ContactShaoju Guo

Shenzhen Traditional Chinese Medicine Hospital

gsj1080@163.com+86 139 2383 8325

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026